DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that Dr. Steve Cutler has been appointed to the newly created position of Chief Operating Officer (COO), ICON plc.
Dr. Cutler joined ICON in November 2011 as Group President, Clinical Research Services. In his new role as COO, Dr. Cutler has responsibility for all of ICON's operational units, covering Early Phase, Clinical, Laboratories, Commercialisation and Outcomes and DOCS FSP & resourcing. Dr Cutler will also take responsibility for ICON's sales and marketing and strategic alliance teams.
Within Dr. Cutler's team, Dr. Nuala Murphy has been appointed President, ICON Clinical Services and Mr. Jim Miskel has been appointed Executive Vice President & General Manager, ICON Laboratory Services.
Dr. Murphy joined ICON in 2012 as Executive Vice President, Global Clinical Operations and Data Management, bringing to ICON over 22 years' experience within the pharmaceutical and CRO industries. In her new role, Dr. Murphy will oversee ICON's global clinical services, comprising clinical and data operations, study start-up, project management, clinical risk management, technology services and clinical scientific operations.
Mr. Miskel joined ICON in November 2013 and will lead ICON's newly combined Central and Bioanalytical laboratories group. He brings a wealth of laboratory and pharmaceutical industry experience to ICON, having previously held senior positions with Harlan Laboratories, MDS Pharma Services, Wyeth Pharmaceuticals and McKinsey & Company.
Commenting on the appointments, Ciaran Murray, Chief Executive Officer, ICON plc, said: "We continually review our structure to ensure that as the market evolves, our organisation can continue to provide customers with innovative and integrated solutions across our various service lines and business units. Bringing all operational units under Steve's leadership will allow us to further enhance the support we can offer to our customers' development programs. I would like to congratulate Steve, Nuala and Jim on their new roles and wish them every success in the future."
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 10,300 employees, operating from 77 locations in 38 countries.
Further information is available at www.iconplc.com
This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.